Dry and Wet Age-Related Macular Degeneration | Treatment Algorithms: Claims Data Analysis | Wet Age-Related Macular Degeneration | US | 2025

With the introduction of extended-duration therapies like Roche’s Vabysmo and Regeneron’s Eylea HD, the U.S. market for wet age-related macular degeneration (AMD) is undergoing significant changes as patients are increasingly transitioning from traditional treatments to these more convenient options. As ophthalmologists and retinal specialists become more accustomed to Vabysmo, its integration into treatment paradigms is becoming clearer. This report leverages commercial and Medicare claims data to evaluate evolving trends in the wet AMD market, including the switching of Eylea patients to Eylea HD and the competitive impact of ranibizumab biosimilars, Byooviz and Cimerli, on Lucentis. Additionally, it explores whether Avastin’s dominance as a first-line therapy is finally diminishing.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed wet AMD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed wet AMD patients?
• How have Vabysmo and Eylea HD been integrated into the treatment algorithm, and what is their source of business?
• What percentage of wet AMD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of wet AMD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key drugs: Avastin, Eylea, Lucentis, Beovu, Mvasi, Zirabev, Vabysmo, Susvimo, Byooviz, Cimerli

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.